Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia

Huafeng Wang, Dandan Zhao, Le Xuan Nguyen, Herman Wu, Ling Li, Dan Dong, Estelle Troadec, Yinghui Zhu, Dinh Hoa Hoang, Anthony S. Stein, Monzr Al Malki, Ibrahim Aldoss, Allen Lin, Lucy Y. Ghoda, Tinisha McDonald, Flavia Pichiorri, Nadia Carlesso, Ya Huei Kuo, Bin Zhang, Jie JinGuido Marcucci

Research output: Contribution to journalArticle

Abstract

The E3 ligase human double minute 2 (HDM2) regulates the activity of the tumor suppressor protein p53. A p53-independent HDM2 expression has been reported on the membrane of cancer cells but not on that of normal cells. Herein, we first showed that membrane HDM2 (mHDM2) is exclusively expressed on human and mouse AML blasts, including leukemia stem cell (LSC)-enriched subpopulations, but not on normal hematopoietic stem cells (HSCs). Higher mHDM2 levels in AML blasts were associated with leukemia-initiating capacity, quiescence, and chemoresistance. We also showed that a synthetic peptide PNC-27 binds to mHDM2 and enhances the interaction of mHDM2 and E-cadherin on the cell membrane; in turn, E-cadherin ubiquitination and degradation lead to membrane damage and cell death of AML blasts by necrobiosis. PNC-27 treatment in vivo resulted in a significant killing of both AML “bulk” blasts and LSCs, as demonstrated respectively in primary and secondary transplant experiments, using both human and murine AML models. Notably, PNC-27 spares normal HSC activity, as demonstrated in primary and secondary BM transplant experiments of wild-type mice. We concluded that mHDM2 represents a novel and unique therapeutic target, and targeting mHDM2 using PNC-27 selectively kills AML cells, including LSCs, with minimal off-target hematopoietic toxicity.

Original languageEnglish (US)
JournalLeukemia
DOIs
StatePublished - Jan 1 2019

Fingerprint

Acute Myeloid Leukemia
Cell Membrane
Membranes
Cadherins
Hematopoietic Stem Cells
Therapeutics
Leukemia
Necrobiotic Disorders
Transplants
Tumor Suppressor Protein p53
Ubiquitin-Protein Ligases
Ubiquitination
Cell Death
Stem Cells
Peptides
PNC-27
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Wang, H., Zhao, D., Nguyen, L. X., Wu, H., Li, L., Dong, D., ... Marcucci, G. (2019). Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia. Leukemia. https://doi.org/10.1038/s41375-019-0522-9

Targeting cell membrane HDM2 : A novel therapeutic approach for acute myeloid leukemia. / Wang, Huafeng; Zhao, Dandan; Nguyen, Le Xuan; Wu, Herman; Li, Ling; Dong, Dan; Troadec, Estelle; Zhu, Yinghui; Hoang, Dinh Hoa; Stein, Anthony S.; Al Malki, Monzr; Aldoss, Ibrahim; Lin, Allen; Ghoda, Lucy Y.; McDonald, Tinisha; Pichiorri, Flavia; Carlesso, Nadia; Kuo, Ya Huei; Zhang, Bin; Jin, Jie; Marcucci, Guido.

In: Leukemia, 01.01.2019.

Research output: Contribution to journalArticle

Wang, H, Zhao, D, Nguyen, LX, Wu, H, Li, L, Dong, D, Troadec, E, Zhu, Y, Hoang, DH, Stein, AS, Al Malki, M, Aldoss, I, Lin, A, Ghoda, LY, McDonald, T, Pichiorri, F, Carlesso, N, Kuo, YH, Zhang, B, Jin, J & Marcucci, G 2019, 'Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia', Leukemia. https://doi.org/10.1038/s41375-019-0522-9
Wang, Huafeng ; Zhao, Dandan ; Nguyen, Le Xuan ; Wu, Herman ; Li, Ling ; Dong, Dan ; Troadec, Estelle ; Zhu, Yinghui ; Hoang, Dinh Hoa ; Stein, Anthony S. ; Al Malki, Monzr ; Aldoss, Ibrahim ; Lin, Allen ; Ghoda, Lucy Y. ; McDonald, Tinisha ; Pichiorri, Flavia ; Carlesso, Nadia ; Kuo, Ya Huei ; Zhang, Bin ; Jin, Jie ; Marcucci, Guido. / Targeting cell membrane HDM2 : A novel therapeutic approach for acute myeloid leukemia. In: Leukemia. 2019.
@article{d5f0d6c4ff4d4e778f1013c936eb93e7,
title = "Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia",
abstract = "The E3 ligase human double minute 2 (HDM2) regulates the activity of the tumor suppressor protein p53. A p53-independent HDM2 expression has been reported on the membrane of cancer cells but not on that of normal cells. Herein, we first showed that membrane HDM2 (mHDM2) is exclusively expressed on human and mouse AML blasts, including leukemia stem cell (LSC)-enriched subpopulations, but not on normal hematopoietic stem cells (HSCs). Higher mHDM2 levels in AML blasts were associated with leukemia-initiating capacity, quiescence, and chemoresistance. We also showed that a synthetic peptide PNC-27 binds to mHDM2 and enhances the interaction of mHDM2 and E-cadherin on the cell membrane; in turn, E-cadherin ubiquitination and degradation lead to membrane damage and cell death of AML blasts by necrobiosis. PNC-27 treatment in vivo resulted in a significant killing of both AML “bulk” blasts and LSCs, as demonstrated respectively in primary and secondary transplant experiments, using both human and murine AML models. Notably, PNC-27 spares normal HSC activity, as demonstrated in primary and secondary BM transplant experiments of wild-type mice. We concluded that mHDM2 represents a novel and unique therapeutic target, and targeting mHDM2 using PNC-27 selectively kills AML cells, including LSCs, with minimal off-target hematopoietic toxicity.",
author = "Huafeng Wang and Dandan Zhao and Nguyen, {Le Xuan} and Herman Wu and Ling Li and Dan Dong and Estelle Troadec and Yinghui Zhu and Hoang, {Dinh Hoa} and Stein, {Anthony S.} and {Al Malki}, Monzr and Ibrahim Aldoss and Allen Lin and Ghoda, {Lucy Y.} and Tinisha McDonald and Flavia Pichiorri and Nadia Carlesso and Kuo, {Ya Huei} and Bin Zhang and Jie Jin and Guido Marcucci",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41375-019-0522-9",
language = "English (US)",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Targeting cell membrane HDM2

T2 - A novel therapeutic approach for acute myeloid leukemia

AU - Wang, Huafeng

AU - Zhao, Dandan

AU - Nguyen, Le Xuan

AU - Wu, Herman

AU - Li, Ling

AU - Dong, Dan

AU - Troadec, Estelle

AU - Zhu, Yinghui

AU - Hoang, Dinh Hoa

AU - Stein, Anthony S.

AU - Al Malki, Monzr

AU - Aldoss, Ibrahim

AU - Lin, Allen

AU - Ghoda, Lucy Y.

AU - McDonald, Tinisha

AU - Pichiorri, Flavia

AU - Carlesso, Nadia

AU - Kuo, Ya Huei

AU - Zhang, Bin

AU - Jin, Jie

AU - Marcucci, Guido

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The E3 ligase human double minute 2 (HDM2) regulates the activity of the tumor suppressor protein p53. A p53-independent HDM2 expression has been reported on the membrane of cancer cells but not on that of normal cells. Herein, we first showed that membrane HDM2 (mHDM2) is exclusively expressed on human and mouse AML blasts, including leukemia stem cell (LSC)-enriched subpopulations, but not on normal hematopoietic stem cells (HSCs). Higher mHDM2 levels in AML blasts were associated with leukemia-initiating capacity, quiescence, and chemoresistance. We also showed that a synthetic peptide PNC-27 binds to mHDM2 and enhances the interaction of mHDM2 and E-cadherin on the cell membrane; in turn, E-cadherin ubiquitination and degradation lead to membrane damage and cell death of AML blasts by necrobiosis. PNC-27 treatment in vivo resulted in a significant killing of both AML “bulk” blasts and LSCs, as demonstrated respectively in primary and secondary transplant experiments, using both human and murine AML models. Notably, PNC-27 spares normal HSC activity, as demonstrated in primary and secondary BM transplant experiments of wild-type mice. We concluded that mHDM2 represents a novel and unique therapeutic target, and targeting mHDM2 using PNC-27 selectively kills AML cells, including LSCs, with minimal off-target hematopoietic toxicity.

AB - The E3 ligase human double minute 2 (HDM2) regulates the activity of the tumor suppressor protein p53. A p53-independent HDM2 expression has been reported on the membrane of cancer cells but not on that of normal cells. Herein, we first showed that membrane HDM2 (mHDM2) is exclusively expressed on human and mouse AML blasts, including leukemia stem cell (LSC)-enriched subpopulations, but not on normal hematopoietic stem cells (HSCs). Higher mHDM2 levels in AML blasts were associated with leukemia-initiating capacity, quiescence, and chemoresistance. We also showed that a synthetic peptide PNC-27 binds to mHDM2 and enhances the interaction of mHDM2 and E-cadherin on the cell membrane; in turn, E-cadherin ubiquitination and degradation lead to membrane damage and cell death of AML blasts by necrobiosis. PNC-27 treatment in vivo resulted in a significant killing of both AML “bulk” blasts and LSCs, as demonstrated respectively in primary and secondary transplant experiments, using both human and murine AML models. Notably, PNC-27 spares normal HSC activity, as demonstrated in primary and secondary BM transplant experiments of wild-type mice. We concluded that mHDM2 represents a novel and unique therapeutic target, and targeting mHDM2 using PNC-27 selectively kills AML cells, including LSCs, with minimal off-target hematopoietic toxicity.

UR - http://www.scopus.com/inward/record.url?scp=85069444007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069444007&partnerID=8YFLogxK

U2 - 10.1038/s41375-019-0522-9

DO - 10.1038/s41375-019-0522-9

M3 - Article

AN - SCOPUS:85069444007

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -